EcoDrugPlus

4-Hydroxyphenylpyruvate Dioxygenase

Ensembl ID : ENSCPOG00000000195
Gene Symbol: HPD
4 Cross references
207 Possible Orthologues:

5'-Nucleotidase Ecto

Ensembl ID : ENSCPOG00000001094
Gene Symbol: NT5E
2 Cross references
250 Possible Orthologues:

5-Hydroxytryptamine Receptor 1a

Ensembl ID : ENSCPOG00000036945
Gene Symbol: HTR1A
2 Cross references
150 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSCPOG00000000103
Gene Symbol: HTR1B
2 Cross references
244 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSCPOG00000003667
Gene Symbol: HTR1E
2 Cross references
157 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSCPOG00000038918
Gene Symbol: HTR2A
2 Cross references
217 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSCPOG00000000433
Gene Symbol: HTR2B
4 Cross references
207 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c

Ensembl ID : ENSCPOG00000037536
Gene Symbol: HTR2C
2 Cross references
227 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSCPOG00000010833
Gene Symbol: HTR3A
2 Cross references
207 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSCPOG00000010829
Gene Symbol: HTR3B
4 Cross references
175 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSCPOG00000012428
Gene Symbol: HTR4
2 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSCPOG00000007970
Gene Symbol: HTR5A
4 Cross references
216 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).